In Europe and the US there are close to 20 million people that live with cancer today, a figure that is increasing. 6.2 million people worldwide died of cancer in 2002. The American Cancer Society estimates that approximately 1.2 million new cancer cases were diagnosed in the year 2002 in the US. Overall annual costs associated with cancer currently amount to $107 billion in the United States alone. The worldwide anti-cancer market was valued at more than $15 billion in 1998 and is projected to nearly double by 2003. Approximately 30% of all collaborative deals are signed in the field of cancer.

Malignant melanoma is the deadliest form of skin cancer and is diagnosed in approximately 132,000 people worldwide each year (2000 data). The incidence of melanoma is increasing at a rate of 3-5% per year. According to the American Cancer Society, the lifetime risk of malignant melanoma in the U.S. has risen from 1/1,500 people in 1935 to 1/74 people in 2000, with a forecast of 1/50 people by 2005. Melanoma currently affects nearly 200,000 people and in 1997 there were an estimated 40,300 new cases and 7,300 deaths. While melanoma is 85-90% curable if identified and treated in its earliest stages, melanoma that has metastasized is deadly. Even after surgical removal, the five-year survival rate for metastatic melanoma is only 20-50%.

The Global Structure of Melanoma R&D is one of the most comprehensive and up to date information sources currently available in the melanoma R&D arena. Information about new innovative cancer therapies suc h as antisense, monoclonal antibodies, gene therapy, antigen- or cellular-based vaccines, liposomal hormones and apoptotic drugs are analyzed in 110 extensive tables and graphs. This report will give you easy-to-read tables with projects classified into well-defined structures based on type of therapy given, effect and mecanism. The graphs provide all the relations of these factors as well as the general and specific trends in the current melanoma pipeline.

Included in this 260+ page report:

Information on more than 140 companies active in melanoma R&D

Information on more than 230 industry related melanoma projects

Data from 140 clinical trials

Information on more than 70 preclinical projects

96 graphs illustrating the most important relations between types of therapy, effects and mecanisms

Advanced analysis of general and specific trends in the pipeline

The data has been structured as follows:

Therapy Given - e.g. Antisense, Biological drug, Cell therapy, Monoclonal antibody, or Small molecular drug etc.

Therapeutic Effect - such as Antiangiogenesis, Immunotherapy, Apoptosis, Cytotoxic, Growth Inhibition, or Vascular Targeting etc.

Mechanism of Action - such as Estrogen modulation, Cell-cycle inhibition, targeting of Bcl-2 or p53, VEGF/VEGFr or EGF/EGFr antagonist, or Tumor antigen etc.

Some of the companies analysed in this report include Abbott, Access Pharmaceuticals,Advanced Life Sciences, Aeterna Laboratories, Amgen, Antigenics, Aptamera, ARC Pharmaceuticals, ARIUS Research, AVAX Technologies, Aventis Pasteur, Biogen, BioNumerik, Biovector, BioVex, Boston Life Sciences, CancerVax, Cell Therapeutics, Centocor, Chiron, Corixa, EntreMed, Epimmune, FIT Biotech, GemVax, Genentech, Genzyme, Human Genome Sciences, ILEX Oncology, ImClone Systems, Immuno-Designed Molecules, IDM, INEX Pharmaceuticals, Johnson & Johnson, Medarex, MediGene, Meditech Research, Merck, Merix Bioscience, Millennium, ML Laboratories (Cobra Therapeutics)., NeoPharm, Northwest Biotherapeutics, Novartis, Oncolytics Biotech, Pfizer, Polymer Laboratories, Progenics Pharma, Regeneron, Roche, Schering AG, Schering-Plough, SciClone Pharmaceuticals, Shire Pharmaceuticals, Sigma-Tau, SuperGen, Transgene, Valentis, Vical, Viventia Biotech, Xcyte, Yamanouchi.

The Global Structure of Melanoma R&D is an excellent source of information providing a solid presentation of exciting and rapidly evolving therapeutics and enabling companies to establish potential partners and competitors.

The report is also available in several different electronic file formats, to enable you with independent updating and structuring of the material.

This report will assist you in:

Tracking cutting edge companies, therapies and new technologies

Rapid identification of partners & competitors

Laying down a comprehensive framework for further analysis of the field

Producing presentations surrounding the development of melanoma therapeutics

Identifying emerging melanoma products & key areas of pharmaceutical R&D

If you would like more information about
The Global Structure of Melanoma R&D please send an email to bioinfo@bioseeker.com or visit our homepage www.BioSeeker.com